AgomAb Therapeutics NV (AGMB)

AgomAb Therapeutics NV Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Selling, General & Admin	12.79	10.13	6.1
Research & Development	48.88	39.31	26.31
Other Operating Expenses	-2.39	-1.42	-1.22
Total Operating Expenses	59.28	48.02	31.19
Operating Income	-59.28	-48.02	-31.19
Interest Income	1.72	1.27	0.3
Interest Expense	-0.13	-0.36	-0.09
Other Non-Operating Income (Expense)	-4.86	0.85	18.96
Total Non-Operating Income (Expense)	-3.27	1.76	19.18
Pretax Income	-62.55	-46.26	-12.01
Provision for Income Taxes	-	-0	0.62
Net Income	-62.55	-46.27	-11.39
Net Income to Common	-62.55	-46.27	-11.39
Shares Outstanding (Basic)	1	1	1
Shares Outstanding (Diluted)	1	1	1
EPS (Basic)	-143.22	-107.09	-35.63
EPS (Diluted)	-143.22	-107.09	-35.63
Shares Outstanding	0.54	0.54	0.54
Free Cash Flow	-51.75	-47.5	-24.59
Free Cash Flow Per Share	-95.62	-87.79	-45.45
EBITDA	-59.06	-47.71	-31.09
EBIT	-59.28	-48.02	-31.19
Effective Tax Rate	0.00%	0.01%	-5.15%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q